Firebrick Pharma

Firebrick Pharma is an Australian pharmaceutical developer, which was founded in 2012 by Dr Peter Molloy and Dr Stephen Goodall with the mission to develop a nasal spray that killed all the germs (viruses or bacteria) responsible for respiratory infections, such as the common cold. After 9 years of development and testing, our first product is now in the final stages of development and is called Nasodine® Nasal Spray* Nasodine Nasal Spray contains the broad-spectrum antimicrobial agent, povidone-iodine. In clinical studies, Nasodine has been shown to be well-tolerated as a four-times-daily nasal spray. Patents have been filed worldwide on its use as a treatment and preventative for the common cold. If approved, Nasodine will be a first-in-class nasal spray medicine that targets the cause of colds, where they start in the nose.*Nasodine Nasal Spray is not yet approved for sale in Australia. We encourage users of our LinkedIn page to read our Social Media and Website Usage Policy (available at which sets out, among other things, your obligations when using our social media pages and websites.